Published in Neurology on February 22, 2000
Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease. J Virol (2001) 2.29
Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis (2005) 1.91
Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS (2011) 1.90
HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol (2010) 1.87
Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol (2005) 1.68
Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog (2009) 1.66
Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol (2005) 1.65
Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis (2008) 1.56
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.47
Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.46
Low atazanavir concentrations in cerebrospinal fluid. AIDS (2009) 1.45
HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog (2011) 1.45
Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS (2009) 1.40
Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol (2011) 1.38
HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med (2012) 1.34
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog (2012) 1.26
Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol (2005) 1.22
HIV and HIV dementia. J Clin Invest (2000) 1.10
Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND). Curr HIV/AIDS Rep (2015) 1.03
HIV-1 pathogenesis: the virus. Cold Spring Harb Perspect Med (2012) 1.03
Chronic alcohol consumption generates a vulnerable immune environment during early SIV infection in rhesus macaques. Alcohol Clin Exp Res (2008) 0.98
Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother (2010) 0.98
Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS (2014) 0.98
HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naïve subjects. J Clin Microbiol (2011) 0.94
Role of endolysosomes in HIV-1 Tat-induced neurotoxicity. ASN Neuro (2012) 0.92
Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS. Curr HIV/AIDS Rep (2015) 0.91
Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. PLoS One (2013) 0.91
Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. J Antimicrob Chemother (2012) 0.90
Feline immunodeficiency virus neuropathogenesis: from cats to calcium. J Neuroimmune Pharmacol (2006) 0.90
Endolysosome involvement in HIV-1 transactivator protein-induced neuronal amyloid beta production. Neurobiol Aging (2013) 0.89
Interplay between Wnt/β-catenin signaling and HIV: virologic and biologic consequences in the CNS. J Neuroimmune Pharmacol (2012) 0.89
Evolving character of chronic central nervous system HIV infection. Semin Neurol (2014) 0.89
The cerebrospinal fluid proteome in HIV infection: change associated with disease severity. Clin Proteomics (2012) 0.88
Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother (2005) 0.86
Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother (2012) 0.84
HIV Associated Neurocognitive Disorders. Infect Dis Rep (2013) 0.84
Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration? Neth J Med (2009) 0.84
Tissue reservoirs of HIV. Curr Opin HIV AIDS (2016) 0.83
Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection. J Neurovirol (2008) 0.82
Ketone bodies protection against HIV-1 Tat-induced neurotoxicity. J Neurochem (2012) 0.80
Transmigration of macrophages across the choroid plexus epithelium in response to the feline immunodeficiency virus. Cell Tissue Res (2012) 0.77
Early detection of simian immunodeficiency virus in the central nervous system following oral administration to rhesus macaques. Front Immunol (2013) 0.77
YKL-40: a candidate biomarker for simian immunodeficiency virus and human immunodeficiency virus encephalitis? Am J Pathol (2008) 0.76
Kinetics of HIV-1 in cerebrospinal fluid and plasma in cryptococcal meningitis. Infect Dis Rep (2012) 0.75
Caffeine Blocks HIV-1 Tat-Induced Amyloid Beta Production and Tau Phosphorylation. J Neuroimmune Pharmacol (2016) 0.75
Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. J Infect Dis (2016) 0.75
Stability of human immunodeficiency virus type 1 RNA in cerebrospinal fluid determined with the AMPLICOR HIV-1 MONITOR test, version 1.5 (ultrasensitive). J Clin Microbiol (2002) 0.75
Untangling the Gordian knot of HIV, stress, and cognitive impairment. Neurobiol Stress (2016) 0.75
Late Onset HIV Encephalopathy in Children with Long-Standing Virologic Suppression Followed by Slow Spontaneous Recovery despite No Change in Antiretroviral Therapy -Four Case Reports. Pediatr Infect Dis J (2017) 0.75
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
The HNRC 500--neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc (1995) 5.38
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol (1994) 5.36
Cefoxitin as a single-dose treatment for urethritis caused by penicillinase-producing Neisseria gonorrhoeae. N Engl J Med (1979) 5.15
Penicillinase-producing Neisseria gonorrhoeae in Great Britain, 1977-81: alarming increase in incidence and recent development of endemic transmission. Br Med J (Clin Res Ed) (1982) 4.95
Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med (1982) 4.28
Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol (1997) 4.17
Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology (2009) 4.07
Effects of age on tissues and regions of the cerebrum and cerebellum. Neurobiol Aging (2001) 3.68
The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education. Ann Neurol (1990) 3.57
Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol (1997) 3.38
Life quality of patients with chronic obstructive pulmonary disease. Arch Intern Med (1982) 3.30
Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med (1995) 3.28
Detecting significant change in neuropsychological test performance: a comparison of four models. J Int Neuropsychol Soc (1999) 3.11
Detection of human cytomegalovirus in clinical specimens by DNA-DNA hybridization. J Infect Dis (1984) 3.10
Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology (2001) 2.92
A multimodal assessment of driving performance in HIV infection. Neurology (2004) 2.81
Human immunodeficiency virus infection of human-PBL-SCID mice. Science (1991) 2.77
Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med (1999) 2.67
Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol (1990) 2.66
Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med (1992) 2.57
A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med (1990) 2.48
The determination of low d5-phenylalanine enrichment (0.002-0.09 atom percent excess), after conversion to phenylethylamine, in relation to protein turnover studies by gas chromatography/electron ionization mass spectrometry. Rapid Commun Mass Spectrom (1992) 2.48
Test-retest reliability and practice effects of expanded Halstead-Reitan Neuropsychological Test Battery. J Int Neuropsychol Soc (1999) 2.47
Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology (2002) 2.47
Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med (1987) 2.46
Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group. Ann Intern Med (1990) 2.45
Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology (2005) 2.45
Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group. HIV Neurobehavioral Research Center. Psychosom Med (1994) 2.39
Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. A controlled study. Arch Gen Psychiatry (1988) 2.36
Detecting change: A comparison of three neuropsychological methods, using normal and clinical samples. Arch Clin Neuropsychol (2001) 2.35
Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest (1998) 2.35
Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J Infect Dis (1997) 2.31
A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care (1991) 2.30
Region and tissue differences of metabolites in normally aged brain using multislice 1H magnetic resonance spectroscopic imaging. Magn Reson Med (2001) 2.22
Circuit party attendance, club drug use, and unsafe sex in gay men. J Subst Abuse (2001) 2.22
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med (1992) 2.19
Influence of colony type on susceptibility of gonococci to killing by human serum. J Immunol (1976) 2.14
High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis (1997) 2.14
Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med (1996) 2.10
Localization of human cytomegalovirus in peripheral blood leukocytes by in situ hybridization. J Infect Dis (1990) 2.08
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis (1998) 2.08
Unrestricted replication of human cytomegalovirus in hydrocortisone-treated macrophages. J Virol (1991) 2.07
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med (1997) 2.06
A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med (1991) 2.06
Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med (1982) 2.06
Introduction to background papers for the suggested changes to DSM-IV: cognitive disorders. J Neuropsychiatry Clin Neurosci (1992) 2.04
A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med (1990) 2.04
Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation (1993) 2.02
Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA (1998) 2.00
Stress, vulnerability and adult alcohol relapse. J Stud Alcohol (1995) 2.00
Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol (1997) 2.00
Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis (1994) 1.99
A factor analysis of the Klein sexual orientation grid in two disparate samples. Arch Sex Behav (1993) 1.98
High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis (1995) 1.97
A Chinese version of the Mini-Mental State Examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol (1988) 1.96
A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. J Infect Dis (1993) 1.93
Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology (2000) 1.91
Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol (1999) 1.89
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 1.89
The National NeuroAIDS Tissue Consortium: a new paradigm in brain banking with an emphasis on infectious disease. Neuropathol Appl Neurobiol (2001) 1.86
Episodic and semantic memory: a comparison of amnesic and demented patients. J Clin Exp Neuropsychol (1987) 1.85
Should homosexuals be vaccinated against hepatitis B virus? Cost and benefit assessment. Br Med J (Clin Res Ed) (1983) 1.85
Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol (1999) 1.82
Enzymatic amplification of human cytomegalovirus sequences by polymerase chain reaction. J Clin Microbiol (1989) 1.81
Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology (2008) 1.80
Virologic characterization of primary human immunodeficiency virus type 1 infection in a health care worker following needlestick injury. J Infect Dis (1995) 1.79
Wasp, the Drosophila Wiskott-Aldrich syndrome gene homologue, is required for cell fate decisions mediated by Notch signaling. J Cell Biol (2001) 1.77
The impact of HIV-related neuropsychological dysfunction on driving behavior. The HNRC Group. J Int Neuropsychol Soc (1999) 1.75
Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol (2009) 1.75
Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain (1999) 1.71
Reduced cerebral grey matter observed in alcoholics using magnetic resonance imaging. Alcohol Clin Exp Res (1991) 1.71
Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol (2005) 1.68
Longitudinal analysis of multiple indicators of health decline among spousal caregivers. Ann Behav Med (1997) 1.68
Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology (2007) 1.67